Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2026)

Aquestive Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 78.58% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $86.4 million (up 284.02% YoY), while the FY2025 annual figure was $102.6 million, up 22.76% from the prior year.
• Cash from Financing Activities was $4.4 million for Q1 2026 at Aquestive Therapeutics, up from $660000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $81.7 million in Q1 2024 to a low of -$9.2 million in Q1 2023.
• Historically, Cash from Financing Activities has averaged $12.1 million across 5 years, with a median of $1.7 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities sank 809.17% in 2023, then soared 478988.24% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $234000.0 in 2022, then surged by 1572.22% to $3.9 million in 2023, then slumped by 95.99% to $157000.0 in 2024, then surged by 320.38% to $660000.0 in 2025, then jumped by 570.15% to $4.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $4.4 million (Q1 2026), $660000.0 (Q4 2025), and $81.4 million (Q3 2025), per Business Quant data.